Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website https://www.cardiologyres.org

Original Article

Volume 14, Number 4, August 2023, pages 250-260

The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review

Figures

Figure 1.
Figure 1. PRISMA flow chart.
Figure 2.
Figure 2. Funnel plot of comparison: 9 HR for extended MACE revised, outcome: 9.1 HR for extended MACE. HR: hazard ratio; MACE: major adverse cardiac event.
Figure 3.
Figure 3. HR of MACE of GLP-1 RA versus comparators. GLA: glargine; GLIM: glimepiride; GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; LIR: liraglutide; MACE: major adverse cardiac event; SIT: sitagliptin.
Figure 4.
Figure 4. HR of extended MACE of GLP-1 RA versus comparators. GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; MACE: major adverse cardiac event.
Figure 5.
Figure 5. HR of all CV evets of GLP-1 RA versus comparators. CV: cardiovascular; GLA: glargine; GLIM: glimepiride; GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; LIR: liraglutide; SIT: sitagliptin.
Figure 6.
Figure 6. HR of HF of GLP-1 RA versus comparators including hospitalization for HF (upper half) and occurrence of HF (lower half). CV: cardiovascular; GLA: glargine; GLIM: glimepiride; GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; LIR: liraglutide; SIT: sitagliptin.
Figure 7.
Figure 7. HR of stroke of GLP-1 RA versus comparators. GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio.
Figure 8.
Figure 8. HR of myocardial infarction of GLP-1 RA versus comparators. GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio.
Figure 9.
Figure 9. HR of all-cause mortality of GLP-1 RA versus comparators. GLA: glargine; GLIM: glimepiride; GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; LIR: liraglutide; SIT: sitagliptin.
Figure 10.
Figure 10. HR of CV death of GLP-1 RA versus comparators. CV: cardiovascular; GLA: glargine; GLIM: glimepiride; GLP-1 RA: glucagon-like peptide 1 receptor agonist; HR: hazard ratio; LIR: liraglutide; SIT: sitagliptin.